{"transactions":[{"id":4629156,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-02T21:19:35.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":4.51,"value":90200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":861076,"source":{"system":"sec-edgar","filing":"0001213900-26-106531","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777328/000121390026106531/ownership.xml","form_type":"4"}},{"id":4629158,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2026-10-02T21:19:22.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":4.511,"value":135330.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1328130,"source":{"system":"sec-edgar","filing":"0001213900-26-106530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1573235/000121390026106530/ownership.xml","form_type":"4"}},{"id":4627030,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:31:26.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":107000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The canceled option provided for vesting in 4 equal installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":107000},"source":{"system":"sec-edgar","filing":"0001213900-26-103540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1351779/000121390026103540/ownership.xml","form_type":"4"}},{"id":4627029,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:31:26.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The canceled option provided for vesting in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024."}],"balance_after":0,"derivative":{"exercise_price":10.4,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-26-103540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1351779/000121390026103540/ownership.xml","form_type":"4"}},{"id":4627028,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:31:26.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":97000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The canceled option provided for vesting in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022."}],"balance_after":0,"derivative":{"exercise_price":8.14,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":97000},"source":{"system":"sec-edgar","filing":"0001213900-26-103540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1351779/000121390026103540/ownership.xml","form_type":"4"}},{"id":4627027,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:31:26.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":49000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The canceled option provided for vesting in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the issuer's share price reaching $8.00, $9.50 and $12.50 per share, respectively. Only the first share price target was achieved, and accordingly only 49,000 of the options vested."}],"balance_after":0,"derivative":{"exercise_price":7.77,"expiration_date":"2027-06-30","underlying":"Common Stock","underlying_shares":49000},"source":{"system":"sec-edgar","filing":"0001213900-26-103540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351779/000121390026103540/ownership.xml","form_type":"4"}},{"id":4627026,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:31:26.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":190000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The canceled option provided for vesting in 4 equal installments as follows: 47,500 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.8,"expiration_date":"2030-01-08","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001213900-26-103540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351779/000121390026103540/ownership.xml","form_type":"4"}},{"id":4627025,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:31:26.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":196500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The canceled option provided for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022."}],"balance_after":0,"derivative":{"exercise_price":3.16,"expiration_date":"2029-09-11","underlying":"Common Stock","underlying_shares":196500},"source":{"system":"sec-edgar","filing":"0001213900-26-103540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351779/000121390026103540/ownership.xml","form_type":"4"}},{"id":4627024,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-25T20:31:26.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":368765,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 368,765 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the \"Plan\"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan."}],"balance_after":4140505,"source":{"system":"sec-edgar","filing":"0001213900-26-103540","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351779/000121390026103540/ownership.xml","form_type":"4"}},{"id":4627023,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-25T20:31:26.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":349497,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."}],"balance_after":3771740,"source":{"system":"sec-edgar","filing":"0001213900-26-103540","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351779/000121390026103540/ownership.xml","form_type":"4"}},{"id":4626994,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:31:13.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":36000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The canceled option provided for vesting in 4 equal installments as follows: 9,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001213900-26-103538","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1573235/000121390026103538/ownership.xml","form_type":"4"}},{"id":4626993,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:31:13.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The canceled option provided for vesting in 4 equal installments as follows: 12,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024."}],"balance_after":0,"derivative":{"exercise_price":10.4,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-26-103538","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1573235/000121390026103538/ownership.xml","form_type":"4"}},{"id":4626992,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:31:13.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The canceled option provided for vesting in 16 equal installments of 6,250 on the first day of every three-month period beginning November 1, 2019. Of the vested options, 50,000 were previously exercised."}],"balance_after":0,"derivative":{"exercise_price":3.69,"expiration_date":"2029-09-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-26-103538","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1573235/000121390026103538/ownership.xml","form_type":"4"}},{"id":4626991,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2026-09-25T20:31:13.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":209291,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the \"Plan\"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan."}],"balance_after":1358130,"source":{"system":"sec-edgar","filing":"0001213900-26-103538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1573235/000121390026103538/ownership.xml","form_type":"4"}},{"id":4626990,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2026-09-25T20:31:13.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":75455,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 75,455 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."}],"balance_after":1148839,"source":{"system":"sec-edgar","filing":"0001213900-26-103538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1573235/000121390026103538/ownership.xml","form_type":"4"}},{"id":4627008,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":72000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The canceled option provided for vesting in 4 equal installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627007,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024."}],"balance_after":0,"derivative":{"exercise_price":10.4,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627006,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The canceled option provided for vesting in 4 equal installments of 11,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022."}],"balance_after":0,"derivative":{"exercise_price":8.14,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627005,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":69999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The canceled option provided for vesting in 3 equal installments of 23,333 on each of December 31, 2017, December 31, 2018 and December 31, 2019."}],"balance_after":0,"derivative":{"exercise_price":7.77,"expiration_date":"2027-06-30","underlying":"Common Stock","underlying_shares":69999},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627004,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.8,"expiration_date":"2030-01-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627003,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":104000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The canceled option provided for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022."}],"balance_after":0,"derivative":{"exercise_price":3.16,"expiration_date":"2029-09-11","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627002,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":209291,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the \"Plan\"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan."}],"balance_after":1550554,"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627001,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":208125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."}],"balance_after":1341263,"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4626995,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-25T20:30:46.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":209291,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the \"Plan\"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan."}],"balance_after":881076,"source":{"system":"sec-edgar","filing":"0001213900-26-103535","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777328/000121390026103535/ownership.xml","form_type":"4"}},{"id":718773,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Stock option (right to buy)","published_at":"2026-07-02T21:00:11.000Z","date":"2026-07-02","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vested and became exercisable in 16 equal installments of 6,250 on the first day of every three-month period beginning November 1, 2019."}],"balance_after":50000,"derivative":{"exercise_price":3.69,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-26-075070","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026075070/ownership.xml","form_type":"4"}},{"id":718772,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2026-07-02T21:00:11.000Z","date":"2026-07-02","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":3.69,"value":184500.0,"ownership":{"direct":true},"balance_after":1073384,"source":{"system":"sec-edgar","filing":"0001213900-26-075070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026075070/ownership.xml","form_type":"4"}},{"id":718771,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2026-07-02T21:00:11.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":137000,"price":4.463,"value":611431.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.7652, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1023384,"source":{"system":"sec-edgar","filing":"0001213900-26-075070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026075070/ownership.xml","form_type":"4"}},{"id":718769,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T21:00:07.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":73360,"price":4.5085,"value":330743.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":671785,"source":{"system":"sec-edgar","filing":"0001213900-26-075069","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026075069/ownership.xml","form_type":"4"}},{"id":824442,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-31T20:10:40.000Z","date":"2026-03-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":44818,"price":3.31,"value":148347.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share."}],"balance_after":3422243,"source":{"system":"sec-edgar","filing":"0001213900-26-037447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026037447/ownership.xml","form_type":"4"}},{"id":824441,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-31T20:10:28.000Z","date":"2026-03-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":435084,"price":3.31,"value":1440128.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share."}],"balance_after":1133138,"source":{"system":"sec-edgar","filing":"0001213900-26-037446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026037446/ownership.xml","form_type":"4"}},{"id":835482,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-18T21:46:58.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":119558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."}],"balance_after":1568222,"source":{"system":"sec-edgar","filing":"0001213900-26-031015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026031015/ownership.xml","form_type":"4"}},{"id":835481,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-18T21:46:36.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":167005,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."}],"balance_after":3422243,"source":{"system":"sec-edgar","filing":"0001213900-26-031013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026031013/ownership.xml","form_type":"4"}},{"id":835480,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2026-03-18T21:46:15.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":95889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."}],"balance_after":1160384,"source":{"system":"sec-edgar","filing":"0001213900-26-031012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026031012/ownership.xml","form_type":"4"}},{"id":835479,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-18T21:45:50.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":95889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."}],"balance_after":745145,"source":{"system":"sec-edgar","filing":"0001213900-26-031011","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026031011/ownership.xml","form_type":"4"}},{"id":842130,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-16T20:06:04.000Z","date":"2026-03-12","kind":"gift","planned":false,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a charitable donation and is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee."}],"balance_after":3255238,"source":{"system":"sec-edgar","filing":"0001213900-26-028291","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026028291/ownership.xml","form_type":"4"}},{"id":928072,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Performance Stock Units","published_at":"2026-01-29T21:05:35.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001213900-26-009477","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009477/ownership.xml","form_type":"4"}},{"id":928071,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2026-01-29T21:05:35.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."}],"balance_after":1064495,"source":{"system":"sec-edgar","filing":"0001213900-26-009477","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009477/ownership.xml","form_type":"4"}},{"id":928070,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Performance Stock Units","published_at":"2026-01-29T21:05:33.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001213900-26-009478","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009478/ownership.xml","form_type":"4"}},{"id":928069,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-29T21:05:33.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."}],"balance_after":1448664,"source":{"system":"sec-edgar","filing":"0001213900-26-009478","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009478/ownership.xml","form_type":"4"}},{"id":928068,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2026-01-29T21:05:32.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001213900-26-009476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009476/ownership.xml","form_type":"4"}},{"id":928067,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-29T21:05:32.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."}],"balance_after":649256,"source":{"system":"sec-edgar","filing":"0001213900-26-009476","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009476/ownership.xml","form_type":"4"}},{"id":928066,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Stock Units","published_at":"2026-01-29T21:05:30.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":false,"shares":109000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":109000},"source":{"system":"sec-edgar","filing":"0001213900-26-009479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009479/ownership.xml","form_type":"4"}},{"id":928065,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-29T21:05:30.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":true,"shares":109000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."}],"balance_after":3355238,"source":{"system":"sec-edgar","filing":"0001213900-26-009479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009479/ownership.xml","form_type":"4"}},{"id":934482,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-21T21:30:02.000Z","date":"2026-01-14","kind":"gift","planned":false,"acquired":false,"shares":86166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a charitable donation and is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee."}],"balance_after":1343498,"source":{"system":"sec-edgar","filing":"0001213900-26-006215","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026006215/ownership.xml","form_type":"4"}},{"id":952503,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55653,"kind":"person","name":"Reznick Yehuda","position":1,"cik":"0002015556","reported_name":"Reznick Yehuda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-05T22:21:36.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."}],"balance_after":105180,"source":{"system":"sec-edgar","filing":"0001213900-26-001282","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001282/ownership.xml","form_type":"4"}},{"id":952502,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55653,"kind":"person","name":"Reznick Yehuda","position":1,"cik":"0002015556","reported_name":"Reznick Yehuda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-05T22:21:36.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."}],"balance_after":98930,"source":{"system":"sec-edgar","filing":"0001213900-26-001282","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001282/ownership.xml","form_type":"4"}},{"id":952501,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Stock Units","published_at":"2026-01-05T22:21:20.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":109000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."}],"balance_after":109000,"derivative":{"underlying":"Common Stock","underlying_shares":109000},"source":{"system":"sec-edgar","filing":"0001213900-26-001280","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001280/ownership.xml","form_type":"4"}},{"id":952500,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-05T22:21:20.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":327000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."}],"balance_after":3246238,"source":{"system":"sec-edgar","filing":"0001213900-26-001280","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001280/ownership.xml","form_type":"4"}},{"id":952499,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-05T22:21:20.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":232640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."}],"balance_after":2919238,"source":{"system":"sec-edgar","filing":"0001213900-26-001280","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001280/ownership.xml","form_type":"4"}},{"id":952498,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Performance Stock Units","published_at":"2026-01-05T22:21:03.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."}],"balance_after":19000,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001213900-26-001279","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001279/ownership.xml","form_type":"4"}},{"id":952497,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-05T22:21:03.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."}],"balance_after":1429664,"source":{"system":"sec-edgar","filing":"0001213900-26-001279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001279/ownership.xml","form_type":"4"}},{"id":952496,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-05T22:21:03.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":121331,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."}],"balance_after":1314664,"source":{"system":"sec-edgar","filing":"0001213900-26-001279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001279/ownership.xml","form_type":"4"}},{"id":952495,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Performance Stock Units","published_at":"2026-01-05T22:20:45.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."}],"balance_after":19000,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001213900-26-001278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001278/ownership.xml","form_type":"4"}},{"id":952494,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2026-01-05T22:20:45.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."}],"balance_after":1045495,"source":{"system":"sec-edgar","filing":"0001213900-26-001278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001278/ownership.xml","form_type":"4"}},{"id":952493,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2026-01-05T22:20:45.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":97328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."}],"balance_after":930495,"source":{"system":"sec-edgar","filing":"0001213900-26-001278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001278/ownership.xml","form_type":"4"}},{"id":952492,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70395,"kind":"person","name":"Shapiro Benjamin","position":1,"cik":"0001974846","reported_name":"Shapiro Benjamin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-05T22:20:23.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."}],"balance_after":123220,"source":{"system":"sec-edgar","filing":"0001213900-26-001277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001277/ownership.xml","form_type":"4"}},{"id":952491,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70395,"kind":"person","name":"Shapiro Benjamin","position":1,"cik":"0001974846","reported_name":"Shapiro Benjamin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-05T22:20:23.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."}],"balance_after":119720,"source":{"system":"sec-edgar","filing":"0001213900-26-001277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001277/ownership.xml","form_type":"4"}},{"id":952490,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70394,"kind":"person","name":"Mayer Arie","position":1,"cik":"0001796583","reported_name":"Mayer Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-05T22:20:05.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":4900,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."}],"balance_after":168009,"source":{"system":"sec-edgar","filing":"0001213900-26-001275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001275/ownership.xml","form_type":"4"}},{"id":952489,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70394,"kind":"person","name":"Mayer Arie","position":1,"cik":"0001796583","reported_name":"Mayer Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-05T22:20:05.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."}],"balance_after":163109,"source":{"system":"sec-edgar","filing":"0001213900-26-001275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001275/ownership.xml","form_type":"4"}},{"id":955447,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70620,"kind":"person","name":"Aghion Daniel","position":1,"cik":"0002004805","reported_name":"Aghion Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-03T01:02:47.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."}],"balance_after":113441,"source":{"system":"sec-edgar","filing":"0001213900-26-000661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026000661/ownership.xml","form_type":"4"}},{"id":955446,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70620,"kind":"person","name":"Aghion Daniel","position":1,"cik":"0002004805","reported_name":"Aghion Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-03T01:02:47.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."}],"balance_after":107191,"source":{"system":"sec-edgar","filing":"0001213900-26-000661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026000661/ownership.xml","form_type":"4"}},{"id":955445,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2026-01-03T01:00:51.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."}],"balance_after":19000,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001213900-26-000658","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026000658/ownership.xml","form_type":"4"}},{"id":955444,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-03T01:00:51.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."}],"balance_after":630256,"source":{"system":"sec-edgar","filing":"0001213900-26-000658","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026000658/ownership.xml","form_type":"4"}},{"id":955443,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-03T01:00:51.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":81216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."}],"balance_after":515256,"source":{"system":"sec-edgar","filing":"0001213900-26-000658","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026000658/ownership.xml","form_type":"4"}},{"id":1118369,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70394,"kind":"person","name":"Mayer Arie","position":1,"cik":"0001796583","reported_name":"Mayer Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:08:35.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":6975,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":133109,"source":{"system":"sec-edgar","filing":"0001213900-25-052624","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025052624/ownership.xml","form_type":"4"}},{"id":1118368,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70394,"kind":"person","name":"Mayer Arie","position":1,"cik":"0001796583","reported_name":"Mayer Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:08:35.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":126134,"source":{"system":"sec-edgar","filing":"0001213900-25-052624","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025052624/ownership.xml","form_type":"4"}},{"id":1118367,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70620,"kind":"person","name":"Aghion Daniel","position":1,"cik":"0002004805","reported_name":"Aghion Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:08:22.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":8371,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":77191,"source":{"system":"sec-edgar","filing":"0001213900-25-052623","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025052623/ownership.xml","form_type":"4"}},{"id":1118366,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70620,"kind":"person","name":"Aghion Daniel","position":1,"cik":"0002004805","reported_name":"Aghion Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:08:22.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":". Represents Restricted Stock Units (\"RSUs\") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":68820,"source":{"system":"sec-edgar","filing":"0001213900-25-052623","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025052623/ownership.xml","form_type":"4"}},{"id":1118365,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55653,"kind":"person","name":"Reznick Yehuda","position":1,"cik":"0002015556","reported_name":"Reznick Yehuda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:08:06.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":8370,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":68930,"source":{"system":"sec-edgar","filing":"0001213900-25-052622","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025052622/ownership.xml","form_type":"4"}},{"id":1118364,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55653,"kind":"person","name":"Reznick Yehuda","position":1,"cik":"0002015556","reported_name":"Reznick Yehuda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:08:06.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":60560,"source":{"system":"sec-edgar","filing":"0001213900-25-052622","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025052622/ownership.xml","form_type":"4"}},{"id":1118363,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":78757,"kind":"person","name":"Sank Leonard","position":1,"cik":"0001416089","reported_name":"Sank Leonard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:07:47.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":6510,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":134531,"source":{"system":"sec-edgar","filing":"0001213900-25-052620","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025052620/ownership.xml","form_type":"4"}},{"id":1118362,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":78757,"kind":"person","name":"Sank Leonard","position":1,"cik":"0001416089","reported_name":"Sank Leonard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:07:47.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":128021,"source":{"system":"sec-edgar","filing":"0001213900-25-052620","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025052620/ownership.xml","form_type":"4"}},{"id":1118361,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70395,"kind":"person","name":"Shapiro Benjamin","position":1,"cik":"0001974846","reported_name":"Shapiro Benjamin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:07:04.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":4650,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":89720,"source":{"system":"sec-edgar","filing":"0001213900-25-052618","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025052618/ownership.xml","form_type":"4"}},{"id":1118360,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70395,"kind":"person","name":"Shapiro Benjamin","position":1,"cik":"0001974846","reported_name":"Shapiro Benjamin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:07:04.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":85070,"source":{"system":"sec-edgar","filing":"0001213900-25-052618","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025052618/ownership.xml","form_type":"4"}},{"id":1274396,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:37.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":66667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares issued on settlement of PSUs previously granted on February 3, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":1193333,"source":{"system":"sec-edgar","filing":"0001213900-25-012241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012241/ownership.xml","form_type":"4"}},{"id":1274395,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:37.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":1126666,"source":{"system":"sec-edgar","filing":"0001213900-25-012241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012241/ownership.xml","form_type":"4"}},{"id":1274394,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:37.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":74000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued on settlement of performance stock units (\"PSUs\") previously granted on January 4, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":1074666,"source":{"system":"sec-edgar","filing":"0001213900-25-012241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012241/ownership.xml","form_type":"4"}},{"id":1274393,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:21.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":33334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares issued on settlement of PSUs previously granted on February 3, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":833167,"source":{"system":"sec-edgar","filing":"0001213900-25-012240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012240/ownership.xml","form_type":"4"}},{"id":1274392,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:21.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":48500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":799833,"source":{"system":"sec-edgar","filing":"0001213900-25-012240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012240/ownership.xml","form_type":"4"}},{"id":1274391,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:21.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued on settlement of performance stock units (\"PSUs\") previously granted on January 4, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":751333,"source":{"system":"sec-edgar","filing":"0001213900-25-012240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012240/ownership.xml","form_type":"4"}},{"id":1274390,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:05.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares issued on settlement of PSUs previously granted on February 3, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":2686598,"source":{"system":"sec-edgar","filing":"0001213900-25-012239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012239/ownership.xml","form_type":"4"}},{"id":1274389,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:05.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":186000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":2586598,"source":{"system":"sec-edgar","filing":"0001213900-25-012239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012239/ownership.xml","form_type":"4"}},{"id":1274388,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:05.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":141000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued on settlement of performance stock units (\"PSUs\") previously granted on January 4, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":2400598,"source":{"system":"sec-edgar","filing":"0001213900-25-012239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012239/ownership.xml","form_type":"4"}},{"id":1274387,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-11T21:30:51.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":434040,"source":{"system":"sec-edgar","filing":"0001213900-25-012238","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012238/ownership.xml","form_type":"4"}},{"id":1274386,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-11T21:30:51.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued on settlement of performance stock units (\"PSUs\") previously granted on June 20, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":392040,"source":{"system":"sec-edgar","filing":"0001213900-25-012238","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012238/ownership.xml","form_type":"4"}},{"id":1311341,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-06T21:10:11.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":433500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in quarterly installments of approximately 36,125 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":2259598,"source":{"system":"sec-edgar","filing":"0001213900-25-001168","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025001168/ownership.xml","form_type":"4"}},{"id":1311340,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-06T21:10:10.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":188000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in quarterly installments of approximately 15,666 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":358040,"source":{"system":"sec-edgar","filing":"0001213900-25-001166","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025001166/ownership.xml","form_type":"4"}},{"id":1311339,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-06T21:10:09.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":207000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in quarterly installments of approximately 17,250 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":1000666,"source":{"system":"sec-edgar","filing":"0001213900-25-001169","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025001169/ownership.xml","form_type":"4"}},{"id":1311338,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2025-01-06T21:10:08.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":194500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in quarterly installments of approximately 16,208 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":706333,"source":{"system":"sec-edgar","filing":"0001213900-25-001165","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025001165/ownership.xml","form_type":"4"}},{"id":1371699,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-08T21:30:26.000Z","date":"2024-11-07","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of 30,000 Restricted Stock Units (\"RSUs\") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":170040,"source":{"system":"sec-edgar","filing":"0001213900-24-095932","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024095932/ownership.xml","form_type":"4"}},{"id":1371698,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-08T21:30:25.000Z","date":"2024-11-07","kind":"grant","planned":false,"acquired":true,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":1826098,"source":{"system":"sec-edgar","filing":"0001213900-24-095931","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024095931/ownership.xml","form_type":"4"}},{"id":1371697,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-11-08T21:30:23.000Z","date":"2024-11-07","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":793666,"source":{"system":"sec-edgar","filing":"0001213900-24-095930","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024095930/ownership.xml","form_type":"4"}},{"id":1371696,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2024-11-08T21:30:22.000Z","date":"2024-11-07","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":511833,"source":{"system":"sec-edgar","filing":"0001213900-24-095929","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024095929/ownership.xml","form_type":"4"}},{"id":1472334,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-21T20:15:23.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":140040,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of 140,040 Restricted Stock Units (\"RSUs\"), of which 93,360 will vest on June 18, 2026 and the remaining 46,680 will vest in four equal quarterly installments of 11,670 starting September 18, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-24-054781","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024054781/ownership.xml","form_type":"4"}},{"id":1485307,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55653,"kind":"person","name":"Reznick Yehuda","position":1,"cik":"0002015556","reported_name":"Reznick Yehuda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T21:15:29.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":760,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of 760 Restricted Stock Units (\"RSUs\") that will vest in two equal installments on October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":30560,"source":{"system":"sec-edgar","filing":"0001213900-24-051336","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024051336/ownership.xml","form_type":"4"}},{"id":1539345,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55653,"kind":"person","name":"Reznick Yehuda","position":1,"cik":"0002015556","reported_name":"Reznick Yehuda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-19T00:07:41.000Z","date":"2024-04-17","kind":"grant","planned":false,"acquired":true,"shares":29800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents (i) a grant of 22,500 Restricted Stock Units (\"RSUs\") that will vest in equal installments on January 1, 2025, January 1, 2026 and January 1, 2027 and (ii) grants of 5,070 and 2,230 RSUs that will each vest in nearly equal installments on July 1, 2024, October 1, 2024 and January 1, 2025. In each case, the RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":29800,"source":{"system":"sec-edgar","filing":"0001213900-24-034222","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024034222/ownership.xml","form_type":"4"}},{"id":1666797,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":70620,"kind":"person","name":"Aghion Daniel","position":1,"cik":"0002004805","reported_name":"Aghion Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-30T22:30:32.000Z","date":"2024-01-30","kind":"grant","planned":false,"acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in quarterly installments of approximately 937 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":38820,"source":{"system":"sec-edgar","filing":"0001209191-24-002429","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919124002429/doc4.xml","form_type":"4"}},{"id":1684523,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:43:05.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":295500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in equal quarterly installments of 24,625 over a three year period starting January 8, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":763666,"source":{"system":"sec-edgar","filing":"0001209191-24-001154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919124001154/doc4.xml","form_type":"4"}},{"id":1684522,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":19859,"kind":"person","name":"KIDRON NADAV","position":1,"cik":"0001351779","reported_name":"KIDRON NADAV","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-08T21:41:41.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":329000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in quarterly installments of approximately 27,417 over a three year period starting January 8, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":1781098,"source":{"system":"sec-edgar","filing":"0001209191-24-001151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919124001151/doc4.xml","form_type":"4"}},{"id":1684521,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":17853,"kind":"person","name":"Hexter Joshua","position":1,"cik":"0001573235","reported_name":"Hexter Joshua","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CBO"}}],"security":"Common Stock","published_at":"2024-01-08T21:40:12.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":180500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in quarterly installments of approximately 15,042 over a three year period starting January 8,\n2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":481833,"source":{"system":"sec-edgar","filing":"0001209191-24-001148","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919124001148/doc4.xml","form_type":"4"}}],"next_cursor":"2024-01-08T21:40:12.000000Z,1684521"}